{"doi":"10.2337/dc22-2426","title":"A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9–15%: DUAL HIGH Trial","abstract":"OBJECTIVE: In participants with type 2 diabetes (T2D) and HbA1c >9.0-10.0%, guidelines recommend treatment with basal-bolus insulin. RESEARCH DESIGN AND METHODS: This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c ≥9.0-15.0%, previously treated with 2 or 3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72). The primary end point was noninferiority (0.4%) in HbA1c reduction between groups. RESULTS: Among 145 participants (HbA1c 10.8% ± 1.3), there was no statistically significant difference in HbA1c reduction (3.18% ± 2.29 vs. 3.00% ± 1.79, P = 0.65; estimated treatment difference (ETD) 0.18%, 95% CI -0.59, 0.94) between the IDegLira and basal-bolus groups. IDegLira resulted in significantly lower rates of hypoglycemia <70 mg/dL (26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78), and less weight gain (1.24 ± 8.33 vs. 5.84 ± 6.18 kg, P = 0.001; ETD -4.60, 95% CI -7.33, -1.87). CONCLUSIONS: In participants with T2D and HbA1c ≥9.0-15.0%, IDegLira resulted in similar HbA1c reduction, less hypoglycemia, and less weight gain compared with the basal-bolus regimen.","journal":"Diabetes Care","year":2023,"id":338604,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9551,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1071484,"name":"Bobak Moazzami","orcid":"0000-0001-7322-3369","position":1,"is_corresponding":false},{"id":249470,"name":"Maria Florencia Scioscia","orcid":"0000-0001-8128-7119","position":2,"is_corresponding":false},{"id":746772,"name":"Cesar Zambrano","orcid":null,"position":3,"is_corresponding":false},{"id":746773,"name":"Bonnie Albury","orcid":null,"position":4,"is_corresponding":false},{"id":1072171,"name":"Jarrod Saling","orcid":null,"position":5,"is_corresponding":false},{"id":339092,"name":"Priyathama Vellanki","orcid":"0000-0002-6544-015X","position":6,"is_corresponding":false},{"id":263838,"name":"Francisco J. Pasquel","orcid":"0000-0002-3845-6703","position":7,"is_corresponding":false},{"id":263836,"name":"Georgia M. Davis","orcid":"0000-0001-9671-0063","position":8,"is_corresponding":false},{"id":332447,"name":"Maya Fayfman","orcid":"0000-0002-8733-3160","position":9,"is_corresponding":false},{"id":265408,"name":"Limin Peng","orcid":null,"position":10,"is_corresponding":false},{"id":228523,"name":"Guillermo E. Umpierrez","orcid":"0000-0002-3252-5026","position":11,"is_corresponding":false},{"id":249469,"name":"Rodolfo J. Galindo","orcid":"0000-0002-9295-3225","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T01:10:40.496978Z","pmid":"37459574","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}